Skip to main content

Table 2 Treatment outcome of prior enzalutamide and subsequent abiraterone acetate treatment

From: Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis

  Enzalutamide (n = 14)
n (%)
Abiraterone (n = 14)
n (%)
Any PSA decline 13 (93) 5 (36)
PSA decline ≥30 % 9 (64) 1 (7)
PSA decline ≥50 % 7 (50) 1 (7)
Median PFS, mo (95 % CI) 5.0 (3.7–6.4) 3.4 (0.8–6.0)
Type of progression
 PSA PD 10 (72) 8 (57)
 Radiographic PD 3 (21) 5 (36)
 Clinical PD 1 (7) 1 (7)